Cardiac Surgery in a Patient with Haemophilia A

Abstract

In this report we describe the successful cardiac surgery in a patient with haemophilia A. To undergo to triple on-pump coronary artery bypass grafting the level of factor VIII was estimated to be 100 %, during the operation and the first postoperative week. To reach this level, bolus therapy with B-domain deleted recombinant factor VIII was administered in a low substitution scheme. There was no bleeding complication. The patient discharged on the 14th postoperative day.

Cardiac surgery - haemophilia A - factor VIII substitution

References

• 1 Rosendaal F R, Varekamp I, Smit C. et al . Mortality and causes of death in Dutch haemophiliacs. 1973 - 86.  Br J Haematol. 1989;  71 71-76
• 2 Rizza C R, Spooner R JD. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976 - 80: report on behalf of the directors of haemophilia centres in the United Kingdom.  Br Med J. 1983;  286 929-933
• 3 Meade T W, Cooper J A, Stirling Y, Howarth D J, Ruddock V, Miller G J. Factor VIII, ABO blood group and the incidence of ischaemic heart disease.  Br J Haematol. 1994;  88 601-607
• 4 Stieltjes N, Altisent C, Auerswald G, Negrier C, Pouzol P, Reynaud J, Roussel G, Savidge F, Villar A, Schulman S. Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience.  Haemophilia. 2004;  9 452-458
• 5 Sennett M M, Alarcon A P. Successful use of ReFacto continuous infusion in two paediatric patients with severe haemophilia A undergoing orthopaedic surgery.  Haemophilia. 2004;  9 655-660
• 6 Rickard K A. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery.  Haemophilia. 1995;  1 (Suppl 1) 8-13
• 7 Lee C. The use of recombinant Factor VIII products in previously treated patients with haemophilia A: pharmacokinetics, efficacy, safety, and inhibitor development.  Semin Thromb Hemost. 2002;  28 241-246
• 8 Negrier C, Goudement J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group: factor eight bypassing activity.  Thromb Haemost. 1997;  77 1113-1119